Answers are grounded in this paper and cite their sources.
This Viewpoint examines how modern precision oncology clinical trials, bolstered by decentralized trial tools, can enhance access to cancer treatments and reduce the burden of trial participation on clinics and participants.
No takes yet. Share an insight, caveat, or question.
Beg et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: